SER - Serina Therapeutics Inc.
Close
7.98
-0.020 -0.251%
Share volume: 3,785
Last Updated: Fri 30 Aug 2024 10:30:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$8.00
-0.02
-0.25%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-12 | 2022-11-10 | 2023-03-31 | 2023-05-12 | 2023-08-14 | 2023-11-14 | 2024-03-22 | 2024-05-14 | |
| Assets | |||||||||
| Total Assets | 2.579 M | 2.008 M | 3.241 M | 12.531 M | 12.277 M | 12.210 M | 11.965 M | 10.856 M | |
| Current Assets | 1.725 M | 1.187 M | 2.453 M | 1.747 M | 1.350 M | 1.141 M | 754.000 K | 8.937 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.011 M | 720.000 K | 1.804 M | 1.461 M | 1.083 M | 673.000 K | 352.000 K | 166.000 K | |
| Short Term Investments | 1.011 M | 720.000 K | 1.804 M | 1.461 M | 1.083 M | 673.000 K | 352.000 K | 166.000 K | |
| Total Receivables | 12.000 K | 1.000 K | 4.000 K | 6.000 K | 6.000 K | 71.000 K | 57.000 K | 65.000 K | |
| Current Cash | 702.000 K | 466.000 K | 645.000 K | 280.000 K | 261.000 K | 397.000 K | 345.000 K | 8.706 M | |
| Total Non-current Assets | 854.000 K | 821.000 K | 788.000 K | 10.784 M | 10.927 M | 11.069 M | 11.211 M | 1.919 M | |
| Property Plant Equipment | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 564.000 K | |
| Other Assets | 50.000 K | 0.000 | 0.000 | 10.029 M | 10.204 M | 10.379 M | 10.554 M | 731.000 K | |
| Intangible Assets | 804.000 K | 771.000 K | 738.000 K | 705.000 K | 673.000 K | 640.000 K | 607.000 K | 574.000 K | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 2.579 M | 2.008 M | 3.241 M | 12.531 M | 12.277 M | 12.210 M | 11.965 M | 10.856 M | |
| Total liabilities | 15.797 M | 17.112 M | 20.453 M | 32.425 M | 34.452 M | 3.788 M | 6.496 M | 15.165 M | |
| Total current liabilities | 9.085 M | 8.809 M | 10.078 M | 22.525 M | 24.505 M | 3.204 M | 5.914 M | 14.059 M | |
| Accounts Payable | 69.000 K | 59.000 K | 141.000 K | 144.000 K | 230.000 K | 0.000 | 66.000 K | 66.000 K | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 413.000 K | |
| Current long term debt | 6.968 M | 7.298 M | 7.646 M | 20.042 M | 22.943 M | 1.526 M | 3.672 M | 9.746 M | |
| Long term debt | 6.756 M | 8.348 M | 10.478 M | 10.011 M | 10.068 M | 693.000 K | 693.000 K | 693.000 K | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 413.000 K | |
| Minority interest | -44.000 K | -45.000 K | -103.000 K | -111.000 K | -121.000 K | -109.000 K | -111.000 K | 0.000 | |
| Total Shareholder equity | -13.218 M | -15.104 M | -17.212 M | -19.894 M | -22.175 M | 8.422 M | 5.469 M | -4.309 M | |
| Common stock | 1.062 M | 1.062 M | 1.063 M | 1.063 M | 1.063 M | 1.063 M | 1.042 M | 2.790 M | |
| Retained earnings | -111.072 M | -113.507 M | -116.210 M | -119.487 M | -122.156 M | -127.557 M | -131.013 M | -5.435 M |